Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

Cytomegalovirus (CMV) Clinical Trial

Official title:
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

Status Completed

Clinical Trial Summary

The purpose of this study is to compare the efficacy of maribavir to investigator-assigned anti-Cytomegalovirus (CMV) therapy in CMV viremia clearance in transplant recipients who are refractory or resistant to prior anti-CMV treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02931539
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 3
Start date	December 22, 2016
Completion date	August 17, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05319353` - A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV Infection	Phase 3
Completed	`NCT05571137` - A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
Not yet recruiting	`NCT06243731` - A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
Completed	`NCT05576805` - A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada
Not yet recruiting	`NCT06213974` - A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
Completed	`NCT02775240` - Study of SHP620 (Maribavir) in Healthy Adults	Phase 1
Completed	`NCT01611974` - Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients	Phase 2
Completed	`NCT05137717` - A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection	Phase 3
Completed	`NCT02927067` - A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants	Phase 3